Humana has added veteran healthcare investor Robert S. Field to its board of directors, strengthening the managed care giant's capital markets and governance expertise at a challenging time for its Medicare Advantage strategy.
The company said Field was elected to the board effective immediately following Humana’s 2026 annual meeting of stockholders, scheduled for April 16. His appointment will expand the board from 10 to 11 members.
Field is principal and managing member of ηMed Capital Management, an investment firm focused on US healthcare services companies, primarily in the managed care sector. He previously served as a senior analyst at Luxor Capital, where he led healthcare services investments. Earlier in his career, he worked as an associate at McKinsey & Company and practiced antitrust law at Vinson & Elkins LLP.
“We are pleased to welcome Rob and are confident that the investor perspective he has developed over more than two decades as a healthcare investor will bring meaningful insight to our Board,” said Humana chairman Kurt J. Hilzinger. “His deep expertise across investment evaluation, risk oversight, and capital allocation - along with his strong understanding of legal and regulatory dynamics in the healthcare sector - will be valuable as Humana executes on its strategy to drive profitable, sustainable growth and long-term shareholder value.”
The company said his appointment followed a search process led by the board and informed by shareholder engagement, including input from John Petry, managing member of Sessa Capital, as part of its ongoing board refreshment and governance efforts.
Field joins Humana as the insurer manages a period of heightened scrutiny around Medicare Advantage (MA) performance, reimbursement and quality ratings.
Humana generates the bulk of its premium revenue from government-sponsored programs, with MA and related products accounting for roughly 80% or more of premiums and services revenue in recent filings. The company has been one of the largest share gainers in the MA market, with strong enrollment growth in recent annual election periods, even as some carriers have scaled back in selected geographies.
That growth has come alongside pressure on MA economics. After years in which around 94% of Humana’s MA members were enrolled in contracts rated four stars or higher, the company has seen a sharp drop in star ratings for 2025 and 2026. Humana has warned that only about one in five MA members will be in four‑star‑and‑above plans for 2026, down from 25% in 2025 and well below prior levels. The shift is expected to reduce quality bonus payments and weigh on revenue and margins, even though its average rating remains broadly in line with the sector.
Humana has challenged aspects of the Centers for Medicare & Medicaid Services’ 2025 star ratings calculations and has cautioned investors that, absent a favorable outcome, the lower ratings will have a material negative impact on 2026 earnings and cash flow. Management has outlined a multi‑year plan to improve performance, with a stated goal of rebuilding average star ratings to 4.0 by 2028.
In that context, adding a long-time healthcare and managed care investor to the board is likely to be seen as reinforcing oversight of strategy, risk and capital allocation as Humana balances membership growth against profitability and regulatory risk in MA.
Field’s election also reflects the growing role of investors and governance specialists in shaping the boards of large US health insurers.
Humana has faced questions from shareholders over its exposure to MA, volatility in results and the pace of investment in its CenterWell healthcare services business. In its recent proxy and public disclosures, the company has emphasized board refreshment, engagement with investors and alignment with governance expectations of large institutional shareholders.
The company noted that Field’s appointment followed discussions with Sessa Capital, an investor with a history of active involvement in the insurance sector.
Field joins the board as the policy and operating backdrop for MA remains fluid.
In early April, the federal government finalized a 2.48% average pay increase for MA plans for 2027, at the higher end of market expectations and broadly positive for large MA carriers. At the same time, CMS is moving ahead with changes to risk‑adjustment, coding and quality reporting, which could alter the distribution of bonus payments and margins across plans even if aggregate funding remains supportive.
Humana, with its heavy concentration in MA and recent ratings setbacks, is particularly sensitive to those shifts. The company has stressed that it is focusing on operational execution, benefit design and risk score accuracy to stabilize results.
Field’s appointment is another signal that Humana is reshaping its board to match those realities — bringing in a director with deep healthcare investing and regulatory experience as it navigates a more complex, capital‑intensive and politically sensitive phase for Medicare Advantage.
